Remedy Informatics said this week that the Merck Global Health Innovation Fund, the investment arm of pharmaceutical giant Merck, has invested about $6 million in growth capital in the company.

The investment gives Merck a seat on Remedy’s board of directors and the opportunity for additional investments in the future, Remedy said.

The capital from Merck “will fuel our growth here in the US and our expansion into Europe and Latin America," Gary Kennedy, Remedy’s founder and CEO, said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."